Journal article icon

Journal article

The controversial role of as-needed short-acting β2-agonist monotherapy in mild asthma: Short review of current guidelines

Abstract:
The controversy surrounding short-acting β2-agonist (SABA) monotherapy for very mild and mild asthma continues in guidelines despite increasing evidence in favor of combined inhaled corticosteroid/reliever therapy. We herein briefly review the findings from two high-quality randomized controlled trials and other safety data to conclude that the efficacy and safety of SABA monotherapy have been overstated, especially in type-2 high or allergic disease.
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Oxford college:
Kellogg College
Role:
Author
ORCID:
0000-0002-4057-6886
Publisher:
Canadian Thoracic Society Publisher's website
Journal:
Canadian Journal of Respiratory, Critical Care, and Sleep Medicine Journal website
Volume:
5
Issue:
5
Pages:
273-275
Publication date:
2021-08-30
DOI:
EISSN:
2474-5340
ISSN:
2474-5332
Language:
English
Keywords:
Pubs id:
1225732
Local pid:
pubs:1225732
Deposit date:
2022-01-20

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP